突觸核蛋白α(SNCa)重組蛋白
Recombinant Synuclein Alpha (SNCa)
SNC-A; aSYN; PD1; PARK1; PARK4; NACP; Non-A Beta Component Of Alzheimer's Disease Amyloid Precursor Protein; Non-A4 component of amyloid precursor
- 編號RPB222Ra01
- 物種Rattus norvegicus (Rat，大鼠)相同的名稱，不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位細(xì)胞質(zhì)
- 預(yù)測分子量-
- 實(shí)際分子量-(差異分析請參閱說明書)
- 片段與標(biāo)簽
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)-
- 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價(jià)格¥ 1123¥ 2808¥ 5616¥ 16848¥ 42120
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Figure. SDS-PAGE
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個(gè)月，-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB222Ra01 | 突觸核蛋白α(SNCa)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB222Ra01 | 突觸核蛋白α(SNCa)多克隆抗體 | IHC |
| MAB222Ra21 | 突觸核蛋白α(SNCa)單克隆抗體 | WB; IHC; ICC; IP. |
| SEB222Ra | 突觸核蛋白α(SNCa)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB222Ra | 突觸核蛋白α(SNCa)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSB222Ra01 | 突觸核蛋白α(SNCa)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| The Journal of Clinical Investigation | Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration[PubMed: PMC3428100] |
| Neurobiology of Disease | Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission[PubMed: PMC3107939] |
| Nature Communications | Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus[PubMed: PMC3265381] |
| Provisional chapter | Mutations of PARK Genes and Alpha-Synuclein and Parkin Concentrations in Parkinson’s Disease[Intechopen:Source] |
| Nerodegeneration | Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment[pubmed:29326545] |
| Experimental gerontology | The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.[pubmed:29107062] |
| Neurobiology of Disease | Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity[Pubmed: 30521842] |
| molecular and cellular biochemistry | Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model[Pubmed: 31820278] |
| International Journal of Pharmacology | Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease[Pubmed: 32084576] |
| EBioMedicine | Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys[Pubmed: 32810825] |